Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...
Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...
Medizinische Klinik II, Johann Wolfgang Goethe Universität, Frankfurt/Main, Germany
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Methodist Cancer Center, Omaha, Nebraska, United States
Tennessee Oncology, Nashville, Tennessee, United States
Institut Gustave-Roussy, Villejuif, France
Emma Kinderziekenhuis AMC, Amsterdam, Netherlands
Birmingham Children's Hospital, Birmingham, United Kingdom
Institut Gustave Roussy, Villejuif, France
Univeristy of Michigan Cancer Center, Ann Arbor, Michigan, United States
Novartis Investigative site, Stoke-on-Trent, United Kingdom
Multiple Sites, Multiple Cities, United Kingdom
Xavier THOMAS, Lyon, France
Novartis Investigative Site, Lausanne, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.